Patents by Inventor Aaron Garzon
Aaron Garzon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8541605Abstract: The present disclosure provides processes for the preparation of lipid conjugated cyclic carbonate derivatives. More specifically, the present disclosure is based on the finding that reacting lipids, such as, ceramides, with N,N?-disuccinimidyl derivative, resulted in the formation of, isolatable, substituted cyclic [1,3]-dioxan-2-one and [1,3]-dioxan-2-thione compounds. These isolatable cyclic substituted compounds and derivatives thereof may be used for various applications, such as in vaccination.Type: GrantFiled: May 11, 2008Date of Patent: September 24, 2013Assignees: Siolab Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.Inventors: Aaron Garzon, Jean Hildesheim
-
Publication number: 20100305333Abstract: The present disclosure provides processes for the preparation of lipid conjugated cyclic carbonate derivatives. More specifically, the present disclosure is based on the finding that reacting lipids, such as, ceramides, with N,N?-disuccinimidyl derivative, resulted in the formation of, isolatable, substituted cyclic [1,3]-dioxan-2-one and [1,3]-dioxan-2-thione compounds. These isolatable cyclic substituted compounds and derivatives thereof may be used for various applications, such as in vaccination.Type: ApplicationFiled: May 11, 2008Publication date: December 2, 2010Applicants: BIOLAB LTD., NASVAX LTD., YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEMInventors: Aaron Garzon, Jean Hildesheim
-
Publication number: 20070213369Abstract: Novel non-psychotropic cannabinoids are disclosed and pharmaceutical compositions comprising these novel compounds are described for preventing neurotoxicity, neuroinflammation, immune or inflammatory disorders comprising as active ingredient the stereospecific (+) enantiomer, having (3S,4S) configuration of ?6 tetrahydrocannabinol type compounds. The compositions are particularly effective in alleviating and even preventing neurotoxicity due to acute injuries to the central nervous system, including mechanical trauma, compromised or reduced blood supply as may occur in cardiac arrest or stroke, or poisonings. They are also effective in the treatment of certain inflammatory disorders and chronic degenerative diseases characterized by neuronal loss and chronic pain including neuropathic pain.Type: ApplicationFiled: May 14, 2007Publication date: September 13, 2007Applicant: Pharmos CorporationInventors: Aaron Garzon, George Fink
-
Patent number: 7235584Abstract: Novel non-psychotropic cannabinoids are disclosed and pharmaceutical compositions comprising these novel compounds are described for preventing neurotoxicity, neuroinflammation, immune or inflammatory disorders comprising as active ingredient the stereospecific (+) enantiomer, having (3S,4S) configuration of ?6 tetrahydrocannabinol type compounds. The compositions are particularly effective in alleviating and even preventing neurotoxicity due to acute injuries to the central nervous system, including mechanical trauma, compromised or reduced blood supply as may occur in cardiac arrest or stroke, or poisonings. They are also effective in the treatment of certain inflammatory disorders and chronic degenerative diseases characterized by neuronal loss and chronic pain including neuropathic pain.Type: GrantFiled: June 25, 2003Date of Patent: June 26, 2007Assignee: Pharmos CorporationInventors: Aaron Garzon, George Fink
-
Patent number: 7214716Abstract: The invention provides novel pharmaceutical compositions comprising as the active ingredient 4-phenyl pinene derivatives which are specific for the peripheral cannabinoid receptors. In particular, the compounds of the invention binds efficiently to CB2 but do not bind to CB1. The compounds show no activity in behavioral tests in mice which together have been shown to be specific for tetrahydrocannabinol (THC)- type activity in the central nervous system mediated by CB1 but reduce blood pressure, block intestinal motility, and elicit anti-inflammatory and peripheral analgetic activity. The invention also relates to methods of treating, preventing, or managing hypertension, inflammation, pain, gastrointestinal diseases, autoimmune diseases, and tumors with the compounds of the invention.Type: GrantFiled: January 27, 2005Date of Patent: May 8, 2007Assignee: Yissum Research Development Co. of the Hebrew University of JerusalemInventors: Ester Fride, Aviva Breuer, Lumir Hanus, Susanna Tchilibon, Michal Horowitz, Raphael Mechoulam, Aaron Garzon
-
Publication number: 20050192341Abstract: The present invention relates to method of using pharmaceutical compositions that contain, as an active ingredient, non-psychotropic cannabinoids for preventing, alleviating or diminishing cognitive impairment resulting from certain types of surgery, diseases or viral infections, fetal distress, pre-term or low weight delivery, from medical intervention such as certain types of medication, irradiation or electroconvulsive therapy, or for prophylactic use in populations exhibiting mild cognitive impairment, and other populations at risk for chronic neurodegenerative diseases.Type: ApplicationFiled: March 4, 2005Publication date: September 1, 2005Inventors: Seth Kindler, Aaron Garzon, George Fink
-
Publication number: 20050165118Abstract: The invention provides novel pharmaceutical compositions comprising as the active ingredient 4-phenyl pinene derivatives which are specific for the peripheral cannabinoid receptors. In particular, the compounds of the invention binds efficiently to CB2 but do not bind to CB1. The compounds show no activity in behavioral tests in mice which together have been shown to be specific for tetrahydrocannabinol (THC)-type activity in the central nervous system mediated by CB1 but reduce blood pressure, block intestinal motility, and elicit anti-inflammatory and peripheral analgetic activity. The invention also relates to methods of treating, preventing, or managing hypertension, inflammation, pain, gastrointestinal diseases, autoimmune diseases, and tumors with the compounds of the invention.Type: ApplicationFiled: January 27, 2005Publication date: July 28, 2005Applicant: YISSUM RESEARCH DEVELOPMENT CO. OF THE HEBREW UNIVERSITY OF JERUSALEMInventors: Ester Fride, Aviva Breuer, Lumir Hanus, Susanna Tchilibon, Michal Horowitz, Raphael Mechoulam, Aaron Garzon
-
Publication number: 20050137251Abstract: The present invention relates to methods of treatment utilizing pharmaceutical compositions that include as active ingredients non-psychotropic cannabinoid derivatives that modulate the expression of genes involved in inflammatory and immune processes. Regulating the transcription of pro and anti-inflammatory mediators has useful therapeutic application for prevention and treatment of acute and chronic inflammation, autoimmune diseases and related disorders, pain, infections, liver diseases, cardiovascular disorders, gastrointestinal disorders, disorders of the central and peripheral nervous system including neurodegenerative diseases, respiratory diseases, renal diseases, post-operative complications, tissue rejection and certain types of cancer.Type: ApplicationFiled: September 16, 2004Publication date: June 23, 2005Inventors: Aaron Garzon, Ayelet Avraham, George Fink
-
Patent number: 6903137Abstract: The invention provides novel pharmaceutical compositions comprising as the active ingredient 4-phenyl pinene derivatives which are specific for the peripheral cannabinoid receptors. In particular, the compounds of the invention binds efficiently to CB2 but do not bind to CB1. The compounds show no activity in behavioral tests in mice which together have been shown to be specific for tetrahydrocannabinol (THC)-type activity in the central nervous system mediated by CB1 but reduce blood pressure, block intestinal motility, and elicit anti-inflammatory and peripheral analgetic activity. The invention also relates to methods of treating, preventing, or managing hypertension, inflammation, pain, gastrointestinal diseases, autoimmune diseases, and tumors with the compounds of the invention.Type: GrantFiled: April 26, 2002Date of Patent: June 7, 2005Assignee: Yissum Research Development Co. of the Hebrew University of JerusalemInventors: Ester Fride, Aviva Breuer, Lumir Hanus, Susanna Tchilibon, Michal Horowitz, Raphael Mechoulam, Aaron Garzon
-
Patent number: 6864291Abstract: The invention provides novel pharmaceutical compositions comprising as the active ingredient 4-phenyl pinene derivatives which are specific for the peripheral cannabinoid receptors. In particular, the compounds of the invention binds efficiently to CB2 but do not bind to CB1. The compounds show no activity in behavioral tests in mice which together have been shown to be specific for tetrahydrocannabinol (THC)-type activity in the central nervous system mediated by CB1 but reduce blood pressure, block intestinal motility, and elicit anti-inflammatory and peripheral analgetic activity. The invention also relates to methods of treating, preventing, or managing hypertension, inflammation, pain, gastrointestinal diseases, autoimmune diseases, and tumors with the compounds of the invention.Type: GrantFiled: October 30, 2000Date of Patent: March 8, 2005Assignee: Yissum Research Development Co. of the Hebrew University of JerusalemInventors: Ester Fride, Aviva Breuer, Lumir Hanus, Susanna Tchilibon, Michal Horowitz, Raphael Mechoulam, Aaron Garzon
-
Publication number: 20050032881Abstract: Novel non-psychotropic cannabinoids are disclosed and pharmaceutical compositions comprising these novel compounds are described for preventing neurotoxicity, neuroinflammation, immune or inflammatory disorders comprising as active ingredient the stereospecific (+) enantiomer, having (3S,4S) configuration of ?6 tetrahydrocannabinol type compounds. The compositions are particularly effective in alleviating and even preventing neurotoxicity due to acute injuries to the central nervous system, including mechanical trauma, compromised or reduced blood supply as may occur in cardiac arrest or stroke, or poisonings. They are also effective in the treatment of certain inflammatory disorders and chronic degenerative diseases characterized by neuronal loss and chronic pain including neuropathic pain.Type: ApplicationFiled: June 25, 2003Publication date: February 10, 2005Inventors: Aaron Garzon, George Fink
-
Publication number: 20050020544Abstract: The present invention relates to non-classical cannabinoids that are ligands of the peripheral cannabinoid receptor CB2, and to pharmaceutical compositions thereof comprising as an active ingredient novel (+) alpha-pinene derivatives, which are useful for prevention and treatment of autoimmune diseases including but not limited to rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, myasthenia gravis, diabetes mellitus type I, hepatitis, psoriasis, tissue rejection in organ transplants, malabsorption syndromes such as celiac disease, pulmonary diseases such as asthma and Sjögren's syndrome, inflammation including inflammatory bowel disease, pain including peripheral, visceral, neurophathic inflammatory and referred pain, muscle spasticity, cardiovascular disorders including arrhythmia, hypertension and myocardial ischemia, neurological disorders including stroke, migraine and cluster headaches, neurodegenerative diseases including Parkinson's disease, Alzheimer's disease, amyotrophic lateraType: ApplicationFiled: July 20, 2004Publication date: January 27, 2005Inventors: Aaron Garzon, George Fink, Dalit Dar, Naim Menashe, Ayelet Nudelman, Orit Greenberg, Avihai Yacovan
-
Publication number: 20040137608Abstract: The present invention relates to a novel microarray, which may be used to present chemical molecules, and methods of preparing said microarray and screening said microarray.Type: ApplicationFiled: November 26, 2003Publication date: July 15, 2004Inventors: Aaron Garzon, Rick Johnston, Rami Skaliter
-
Patent number: 6610737Abstract: Novel non-psychotropic cannabinoids are disclosed and pharmaceutical compositions comprising these novel compounds are described for preventing neurotoxicity, neuroinflammation, immune or inflammatory disorders comprising as active ingredient the stereospecific (+) enantiomer, having (3S,4S) configuration of &Dgr;6 tetrahydrocannabinol type compounds. The compositions are particularly effective in alleviating and even preventing neurotoxicity due to acute injuries to the central nervous system, including mechanical trauma, compromised or reduced blood supply as may occur in cardiac arrest or stroke, or poisonings. They are also effective in the treatment of certain inflammatory disorders and chronic degenerative diseases characterized by neuronal loss and chronic pain including neuropathic pain.Type: GrantFiled: November 26, 2002Date of Patent: August 26, 2003Assignee: Pharmos CorporationInventors: Aaron Garzon, George Fink
-
Publication number: 20020173528Abstract: The invention provides novel pharmaceutical compositions comprising as the active ingredient 4-phenyl pinene derivatives which are specific for the peripheral cannabinoid receptors. In particular, the compounds of the invention binds efficiently to CB2 but do not bind to CB1. The compounds show no activity in behavioral tests in mice which together have been shown to be specific for tetrahydrocannabinol (THC)-type activity in the central nervous system mediated by CB1 but reduce blood pressure, block intestinal motility, and elicit anti-inflammatory and peripheral analgetic activity. The invention also relates to methods of treating, preventing, or managing hypertension, inflammation, pain, gastrointestinal diseases, autoimmune diseases, and tumors with the compounds of the invention.Type: ApplicationFiled: April 26, 2002Publication date: November 21, 2002Inventors: Ester Fride, Aviva Breuer, Lumir Hanus, Susanna Tchilibon, Michal Horowitz, Raphael Mechoulam, Aaron Garzon
-
Patent number: 5424292Abstract: 5-Aminosalicylic acid derivatives acylated at the amino group with glutamic or aspartic acid and/or having the carboxy group involved in a peptide bond with the leucyl-prolyl residue are useful as pro-drugs of 5-aminosalicylic acid.Type: GrantFiled: March 3, 1993Date of Patent: June 13, 1995Assignee: Depha Team s.r.l.Inventors: Roberto Pellicciari, Aaron Garzon, Carlo Clerici, Camillo M. F. G. Palazzi
-
Patent number: 4943579Abstract: Water-soluble derivatives of camptothecin have the formulae: ##STR1## wherein R' is selected from the group consisting of R=CO CH.sub.2 NH.sub.2.HClR=CO CH.sub.2 NHCH.sub.3.HClR=CO CH.sub.2 NHC.sub.2 H.sub.5.HClR=CO CH.sub.2 N(C.sub.2 H.sub.5).sub.2.HClR=CO CH(NH.sub.2) CH.sub.2 CH.sub.2 CH.sub.2 CH.sub.2 CH.sub.2 NH.sub.2.2HClR=CO CH(NH.sub.2) CH.sub.2 CH.sub.2 COOH. HClR=CO CH.sub.2 CH.sub.2.COO.sup.- Na.sup.+R=HPO.sub.3.sup.- Na.sup.Type: GrantFiled: October 6, 1987Date of Patent: July 24, 1990Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: B. Rao Vishnuvajjala, Aaron Garzon-Aburbeh